AUTHOR=Zhang Ying , Guo Yanyang , Wei Wenjia , Zhang Zhongxiao , Xu Xiaodong 

TITLE=Metabolomics profiling reveals berberine-inhibited inflammatory response in human gingival fibroblasts by regulating the LPS-induced apoptosis signaling pathway

JOURNAL=Frontiers in Pharmacology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.940224

DOI=10.3389/fphar.2022.940224

ISSN=1663-9812

ABSTRACT=<p>This article examines berberine’s biological effects and molecular mechanisms with an inflammatory response model induced by lipopolysaccharide (LPS) in human gingival fibroblasts (HGFs) using metabolomics. The viability of HGFs was determined using the cell counting kit-8 (CCK8). ELISA was used to measure inflammatory cytokines, including interleukin-6 (IL-6), interleukin-1<italic>β</italic> (IL-1<italic>β</italic>), and tumor necrosis factor- <italic>α</italic> (TNF-<italic>α</italic>). An investigation of western blots was conducted to investigate the related proteins of apoptosis. Low concentrations of berberine (0.1, 0.5, and 1 μmol L<sup>−1</sup>) did not affect HGF growth, whereas high concentrations of berberine (5–25 μmol L<sup>−1</sup>) significantly activated cell proliferation. Berberine suppressed the elevated secretion of IL-6, IL-1β, and TNF-α induced by LPS in HGF. Western blot analysis showed that 10 μmol L<sup>−1</sup> of berberine significantly inhibited LPS-induced apoptosis signaling pathway activation. Our results suggested that berberine could inhibit LPS-induced apoptosis and the production of proinflammatory mediators in HGFs cells. Berberine may be a potential therapeutic drug for the management of periodontitis.</p>